Literature DB >> 486847

Changes in the brain catecholamines in patients with dementia of Alzheimer type.

R Adolfsson, C G Gottfries, B E Roos, B Winblad.   

Abstract

Brain monoamine concentrations were determined post mortem in 19 patients with dementia of Alzheimer type. Samples were taken from 10 parts of the brain and compared with an age-matched control group. There were lower mean concentrations of dopamine in the demented group of patients in seven regions of the brain, and two of these were at a significant level. There were also significantly lower concentrations of homovanillic acid in the nucleus caudatus and in the putamen. The means of the concentrations of noradrenaline were also lower, and in the putamen and the cortex gyrus frontalis significant differnces were observed. The 5-hydroxytryptamine concentrations were slightly lower in the demented group but the differences did not reach significance. The degree of intellectual deterioration was negatively correlated with the noradrenaline concentrations in the hypothalamus and the cortex gyrus cinguli.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 486847     DOI: 10.1192/bjp.135.3.216

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  72 in total

1.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

2.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

3.  Neurotoxin-induced DNA damage is persistent in SH-SY5Y cells and LC neurons.

Authors:  Yan Wang; Phillip R Musich; Kui Cui; Yue Zou; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2015-03-01       Impact factor: 3.911

4.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

5.  A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.

Authors:  A Little; R Levy; P Chuaqui-Kidd; D Hand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

Review 6.  Intrinsic regulation of brain inflammatory responses.

Authors:  Elena Galea; Michael T Heneka; Cinzia Dello Russo; Douglas L Feinstein
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

Review 7.  Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment.

Authors:  C G Gottfries
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

8.  Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia.

Authors:  K Fujiyoshi; H Suga; K Okamoto; S Nakamura; M Kameyama
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-07       Impact factor: 10.154

9.  Parkinson's disease and Alzheimer's disease as disorders of the isodendritic core.

Authors:  M N Rossor
Journal:  Br Med J (Clin Res Ed)       Date:  1981-12-12

Review 10.  Good night and good luck: norepinephrine in sleep pharmacology.

Authors:  Heather A Mitchell; David Weinshenker
Journal:  Biochem Pharmacol       Date:  2009-10-13       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.